Article Text

Download PDFPDF
Drug overdose deaths at work, 2011–2016
  1. Hope M Tiesman1,
  2. Srinivas Konda1,
  3. Lauren Cimineri2,
  4. Dawn N Castillo1
  1. 1 Division of Safety Research, National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention (CDC/NIOSH), Morgantown, West Virginia, USA
  2. 2 World Trade Center Health Program, NIOSH, Washington, DC, USA
  1. Correspondence to Dr Hope M Tiesman, Division of Safety Research, National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention (CDC/NIOSH), Morgantown 26505, West Virginia, USA; htiesman{at}cdc.gov

Abstract

Drug overdose fatalities have risen sharply and the impact on US workplaces has not been described. This paper describes US workplace overdose deaths between 2011 and 2016. Drug overdose deaths were identified from the Census of Fatal Occupational Injuries and fatality rates calculated using denominators from the Current Population Survey. Fatality rates were compared among demographic groups and industries. Negative binomial regression was used to analyse trends. Between 2011 and 2016, 760 workplace drug overdoses occurred for a fatality rate of 0.9 per 1 000 000 full-time equivalents (FTEs). Workplace overdose fatality rates significantly increased 24% annually. Workplace overdose fatality rates were highest in transportation and mining industries (3.0 and 2.6 per 1 000 000 FTEs, respectively). One-third of workplace overdose fatalities occurred in workplaces with fewer than 10 employees. Heroin was the single most frequent drug documented in workplace overdose deaths (17%). Workplace overdose deaths were low, but increased considerably over the six-year period. Workplaces are impacted by the national opioid overdose epidemic.

  • overdoses
  • workplace
  • surveillance
View Full Text

Statistics from Altmetric.com

Footnotes

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient consent for publication Not required.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.